Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) EBIT (2019 - 2025)

Allogene Therapeutics' EBIT history spans 7 years, with the latest figure at -$44.9 million for Q3 2025.

  • For Q3 2025, EBIT rose 37.44% year-over-year to -$44.9 million; the TTM value through Sep 2025 reached -$227.4 million, up 23.64%, while the annual FY2024 figure was -$273.2 million, 16.64% up from the prior year.
  • EBIT for Q3 2025 was -$44.9 million at Allogene Therapeutics, up from -$56.8 million in the prior quarter.
  • Across five years, EBIT topped out at $1.7 million in Q4 2021 and bottomed at -$99.1 million in Q1 2023.
  • The 5-year median for EBIT is -$71.4 million (2024), against an average of -$67.6 million.
  • The largest annual shift saw EBIT soared 102.46% in 2021 before it plummeted 5750.91% in 2022.
  • A 5-year view of EBIT shows it stood at $1.7 million in 2021, then tumbled by 5750.91% to -$96.5 million in 2022, then rose by 11.77% to -$85.1 million in 2023, then grew by 28.93% to -$60.5 million in 2024, then grew by 25.77% to -$44.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's EBIT are -$44.9 million (Q3 2025), -$56.8 million (Q2 2025), and -$65.2 million (Q1 2025).